1093192-06-3

Usage

Uses

Used in Pharmaceutical Research:
(S)-methyl 3-(tert-butoxycarbonylamino)-3-methyl-2-((S)-1-phenylethylamino)butanoate is used as a chiral building block for the synthesis of biologically active compounds. Its unique stereochemistry allows for the creation of enantiomerically pure compounds, which is crucial for the development of new drugs and therapeutic agents with improved efficacy and reduced side effects.
Used in Organic Synthesis:
In the field of organic synthesis, (S)-methyl 3-(tert-butoxycarbonylamino)-3-methyl-2-((S)-1-phenylethylamino)butanoate serves as a valuable intermediate for the preparation of various complex organic molecules. Its reactivity and functional group compatibility make it suitable for a wide range of synthetic transformations, facilitating the construction of diverse molecular architectures.
Used in Peptide Chemistry:
(S)-methyl 3-(tert-butoxycarbonylamino)-3-methyl-2-((S)-1-phenylethylamino)butanoate is utilized in peptide chemistry as a non-natural amino acid for the synthesis of peptide-based drugs and bioactive peptides. Its incorporation into peptide sequences can modulate the properties of the resulting peptides, such as stability, bioavailability, and target specificity.
Used in Asymmetric Synthesis:
As a reagent in asymmetric synthesis, (S)-methyl 3-(tert-butoxycarbonylamino)-3-methyl-2-((S)-1-phenylethylamino)butanoate plays a crucial role in the enantioselective formation of chiral centers in target molecules. Its use in this context can enhance the efficiency and selectivity of synthetic processes, leading to the production of enantiomerically pure compounds with potential applications in various industries.

Upstream product

• 1093192-04-1 (S)-methyl 3-methyl-3-nitro-2-(((S)-1-phenylethyl)amino)butanoate 
• 1093192-03-0 (S)-3-methyl-3-nitro-2-(((S)-1-phenylethyl)amino)butanoic acid 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 1093192-05-2 (S)-methyl 3-amino-3-methyl-2-(((S)-1-phenylethyl)amino)butanoate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1363368-24-4 (S)-N-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yI)-4-(4-(2-aminophenyl)buta-1,3-diynyl)benzamide 
• 1363373-88-9 C₂₈H₃₁N₃O₅ 
• 1363373-89-0 C₂₃H₂₃N₃O₃ 
• 1093192-07-4 (S)-2-amino-3-(tert-butoxycarbonylamino)-3-methylbutanoic acid methyl ester 

Relevant academic research and scientific papers

COMPOUND ACTING AS ANTIBIOTICS

The present invention provides a novel antibiotic compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof. The compound of the present invention exhibits excellent antibacterial activity, especially against Gram bacteria. wherein each group is defined as in the description.

Design, synthesis and structure-activity relationship evaluation of novel LpxC inhibitors as Gram-negative antibacterial agents

LpxC inhibitors are new-type antibacterial agents developed in the last twenty years, mainly against Gram-negative bacteria infections. To develop novel LpxC inhibitors with good antibacterial activities and biological metabolism, we summarized the basic skeleton of reported LpxC inhibitors, designed and synthesized several series of compounds and tested their antibacterial activities against Escherichial coli and Pseudomonas aeruginosa in vitro. Structure-activity relationships have been discussed in this article. The metabolism stability of YDL-2, YDL-5, YDL-8, YDL-14, YDL-20–YDL-23 have been evaluated in liver microsomes, which indicated that the 2-amino isopropyl group may be a preferred structure than the 2-hydroxy ethyl group in the design of LpxC inhibitors.

ETHYNYLBENZENE DERIVATIVES

Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.

ANTIBACTERIAL AGENTS

Antibacterial compounds of formula (I) are provided, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.